natgillin/translations-raw huggingface dataset:
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sirturo, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Sirturo in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
What is Sirturo and what is it used for? 
Kaj je zdravilo Sirturo in za kaj se uporablja?
The average time it took to clear the bacteria from the sputum was also shorter for patients in the Sirturo group than for those in the placebo group (83 days versus 125 days). 
Poleg tega je bil tudi povprečni čas, ki je bil potreben za to, da so se bakterije izločile iz sputuma, krajši pri bolnikih v skupini, ki je prejemala zdravilo Sirturo, kot pri tistih v skupini, zdravljeni s placebom (83 dni v primerjavi s 125).
Sirturo is used in combination with other tuberculosis medicines in adults with tuberculosis that is affecting the lung and that is multi-drug resistant (resistant to at least isoniazid and rifampicin, two standard tuberculosis medicines). 
Zdravilo Sirturo se uporablja v kombinaciji z drugimi zdravili za zdravljenje tuberkuloze pri odraslih bolnikih s tuberkulozo, ki prizadene pljuča in je odporna proti več zdravilom (vsaj proti izoniazidu in rifampicinu, ki sta standardni zdravili za zdravljenje tuberkuloze).
Sirturo has been given ‘conditional approval'. 
Zdravilo Sirturo je pridobilo „pogojno dovoljenje za promet“.
Why is Sirturo approved? 
Zakaj je bilo zdravilo Sirturo odobreno?
For practical information about using Sirturo, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Sirturo naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Sirturo is a tuberculosis medicine that contains the active substance bedaquiline. 
Sirturo je zdravilo za zdravljenje tuberkuloze, ki vsebuje zdravilno učinkovino bedakilin.
Treatment should be started and monitored by a doctor who is experienced in the treatment of multi-drug resistant tuberculosis. 
Zdravljenje sme uvesti in spremljati le zdravnik, ki ima izkušnje z zdravljenjem tuberkuloze, odporne proti več zdravilom.
What information is still awaited for Sirturo? 
Katere informacije o zdravilu Sirturo še pričakujemo?
Sirturo can only be obtained with a prescription. 
Izdaja zdravila Sirturo je le na recept.
In a main study in adults with multi-drug resistant tuberculosis affecting the lung, Sirturo was compared with placebo (a dummy treatment) when added to combination treatment with other standard tuberculosis medicines. 
V glavni študiji pri odraslih bolnikih s tuberkulozo, ki je odporna proti več zdravilom in prizadene pljuča, so primerjali zdravilo Sirturo in placebo (zdravilo brez zdravilne učinkovine), ki so ju dodali kombiniranemu zdravljenju z drugimi standardnimi zdravili za tuberkulozo.
There was also a higher number of reported deaths in the Sirturo group. 
Prav tako so v skupini, zdravljeni z zdravilom Sirturo, zabeležili večje število smrtnih primerov.
How does Sirturo work? 
Kako zdravilo Sirturo deluje?
The European Commission granted a marketing authorisation valid throughout the European Union for Sirturo on 05/03/2014. 
Evropska komisija je dovoljenje za promet z zdravilom Sirturo, veljavno po vsej Evropski uniji, izdala <datum izdaje dovoljenja za promet z zdravilom>.
How is Sirturo used? 
Kako se zdravilo Sirturo uporablja?
List of the names, pharmaceutical form, strength of the medicinal products, route of administration, applicants /marketing authorisation holders in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, predlagateljev/imetnikov dovoljenja za promet z zdravilom v državah članicah
This summary was last updated in 10-2018. 
Povzetek je bil nazadnje posodobljen 10-2018.
Further information on Elocta can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Elocta. 
Nadaljnje informacije o zdravilu Elocta so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Elocta.
The injection is given into a vein over several minutes. 
Injicira se v veno v trajanju nekaj minut.
Elocta received a marketing authorisation valid throughout the EU on 19 November 2015. 
Zdravilo Elocta je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 19. novembra 2015.
The European Medicines Agency therefore decided that Elocta's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Elocta večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Elocta? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Elocta?
Other information about Elocta 
Druge informacije o zdravilu Elocta
As for all medicines, data on the use of Elocta are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Elocta stalno spremljajo.
The active substance in Elocta, efmoroctocog alfa, works in the body in the same way as human factor VIII. 
Učinkovina v zdravilu Elocta, efmoroktokog alfa, deluje v telesu enako kot humani faktor VIII.
Hypersensitivity (allergic) reactions are seen rarely with Elocta and these include: swelling of the face, rash, hives, tightness of the chest and difficulty breathing, burning and stinging at the injection site, chills, flushing, itching over the whole body, headache, low blood pressure, lethargy, nausea, restlessness, and a fast heartbeat. 
Pri zdravljenju z zdravilom Elocta se redko pojavijo preobčutljivostne (alergijske) reakcije, ki vključujejo: otekanje obraza, izpuščaj, koprivnico, stiskanje v prsnem košu in težave z dihanjem, pekoč in zbadajoč občutek na mestu injiciranja, mrzlico, vročinske oblive, srbenje po vsem telesu, glavobol, nizek krvni tlak, otopelost, slabost, nemir in hiter srčni utrip.
Why is Elocta authorised in the EU? 
Zakaj je zdravilo Elocta odobreno v EU?
What benefits of Elocta have been shown in studies? 
Kakšne koristi je zdravilo Elocta izkazalo v študijah?
In addition, when bleeding did occur, Elocta treatment was rated as ‘excellent' or ‘good' in more than 78% of cases, with 87% of bleeding episodes resolving with only one injection. 
Poleg tega je bilo ob pojavu krvavitve zdravljenje z zdravilom Elocta v več kot 78 % primerih ocenjeno kot „odlično“ ali „dobro“, pri čemer so 87 % krvavitev obvladali z eno samo injekcijo.
An overview of Elocta and why it is authorised in the EU 
Pregled zdravila Elocta in zakaj je odobreno v EU
What is Elocta and what is it used for? 
Kaj je zdravilo Elocta in za kaj se uporablja?
What are the risks associated with Elocta? 
Kakšna tveganja so povezana z zdravilom Elocta?
In a study in 69 children, Elocta was similarly effective: 2 bleeding episodes occurred per year on average and 81% of bleeding episodes resolved with only one injection. 
V študiji na 69 otrocih je bilo zdravilo Elocta podobno učinkovito: na leto sta se povprečno pojavili dve krvavitvi, pri čemer so 81 % krvavitev obvladali z eno samo injekcijo.
For more information about using Elocta, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Elocta glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Elocta are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Elocta, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Elocta have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Elocta upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
It contains the active substance efmoroctocog alfa. 
Vsebuje učinkovino efmoroktokog alfa.
In a study of 165 adult patients with haemophilia A, patients who were given Elocta as a tailored preventive treatment had around 3 bleeding episodes a year, which compares with 37 episodes a year in patients not given preventive treatment. 
V študiji s 165 odraslimi bolniki s hemofilijo A so imeli bolniki, ki so prejeli zdravilo Elocta kot prilagojeno preventivno zdravljenje, približno tri krvavitve na leto, bolniki, ki niso prejemali preventivnega zdravljenja, pa 37 krvavitev na leto.
The dose and frequency of the injections depend on whether Elocta is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight. 
Odmerek in pogostnost injiciranja sta odvisna od tega, ali se zdravilo Elocta uporablja za zdravljenje ali preprečevanje krvavitev, resnosti bolnikovega pomanjkanja faktorja VIII, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
Studies show that Elocta is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is in line with what is expected for medicines of its kind. 
Študije kažejo, da je zdravilo Elocta učinkovito pri preprečevanju in zdravljenju krvavitev pri bolnikih s hemofilijo A, njegova varnost pa je v skladu s pričakovano varnostjo tovrstnih zdravil.
Elocta is available as a powder and solvent used to make a solution for injection. 
Zdravilo Elocta je na voljo kot prašek in vehikel za pripravo raztopine za injiciranje.
There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control. 
Pri zdravilih s faktorjem VIII obstaja tudi tveganje, da se bodo pri nekaterih bolnikih pojavili zaviralci (protitelesa) faktorja VIII, ki bodo izničili njegovo delovanje ter tako povzročili izgubo nadzora nad krvavitvami.
Two main studies of Elocta showed that the medicine is effective at both preventing and treating bleeding episodes. 
Glavni študiji z zdravilom Elocta sta pokazali, da je učinkovito pri preprečevanju in zdravljenju krvavitev.
Elocta can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia. 
Predpisovanje in izdaja zdravila Elocta je le na recept, zdravljenje z njim pa se sme uvesti samo pod nadzorom zdravnika z izkušnjami z zdravljenjem hemofilije.
Elocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). 
Zdravilo Elocta se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (dedno motnjo strjevanja krvi zaradi pomanjkanja faktorja VIII).
For the full list of side effects and restrictions of Elocta, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Elocta glejte navodilo za uporabo.
How does Elocta work? 
Kako zdravilo Elocta deluje?
How is Elocta used? 
Kako se zdravilo Elocta uporablja?
The Member States shall ensure that the Marketing Authorisation Holder complies with the following requirements in their Member State: 
Države članice bodo poskrbele, da imetnik dovoljenja za promet v njihovi državi članici izpolni naslednje zahteve:
The MULTAQ Information Card should contain the following key safety messages: 
Informativna kartica o zdravilu MULTAQ mora vsebovati naslednja ključna sporočila o varnosti:
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH MORAJO IZPOLNITI DRŽAVE ČLANICE
If ALT levels are confirmed to be ≥3 × ULN after re-measurement, treatment with dronedarone should be withdrawn. 
Če je izvid ALT po ponovni meritvi potrjeno ≥ 3-kratna ZNM, je treba prenehati zdravljenje z dronedaronom.
• That the use of MULTAQ is not recommended in patients with recent (1-3 months) stable NYHA class III heart failure or with LVEF <35%. 
• Zdravila MULTAQ ni priporočljivo uporabljati pri bolnikih z nedavnim (od 1 do 3 mesece) stabilnim srčnim popuščanjem v III. razredu po NYHA ali z LVEF < 35 %.
The content and format of the MULTAQ Information Card, together with the communication and distribution plan should be agreed with the National Competent Authority in each Member State prior to distribution. 
O vsebini in obliki informativne kartice o zdravilu MULTAQ ter o načrtu komunikacije in distribucije le-te, se je potrebno predhodno uskladiti z pristojnimi nacionalnimi organi v vsaki državi članici.
• That patients should be counselled that: they should consult a physician if they develop or experience worsening signs or symptoms of heart failure; they should immediately report to a physician any symptoms of potential liver injury; MULTAQ interacts with a number of medicines; if they consult other doctors they should inform them that they are taking MULTAQ; they should not take St John's Wort with MULTAQ; they should avoid grapefruit juice. 
• Bolnikom je treba povedati, da: se morajo posvetovati z zdravnikom, če so opazili pojav ali so doživeli poslabšanje znakov ali simptomov srčnega popuščanja; morajo nemudoma poročati zdravniku o kakršnihkoli znakih možne poškodbe jeter; zdravilo MULTAQ medsebojno deluje s številnimi zdravili; v primeru posveta pri drugih zdravnikih le-tem povedo, da jemljejo zdravilo MULTAQ; skupaj z zdravilom MULTAQ ne smejo uporabljati šentjanževke; se morajo izogibati grenivkinemu soku.
The MULTAQ Information Card should contain a list of drugs which interact with MULTAQ classified according to the seriousness of the interaction (eg contraindication, not recommended, use with caution). 
Informativna kartica o zdravilu MULTAQ mora obsegati seznam zdravil, ki medsebojno delujejo z zdravilom MULTAQ, razvrščenih glede na resnost medsebojnega delovanja (npr. kontraindicirana, nepriporočljiva, uporabljajte previdno).
• That plasma creatinine levels may rise initially due to inhibition of the renal tubular excretion of creatinine and are not necessarily indicative of a deterioration in renal function. 
• Uvodoma se lahko zaradi zavrtja ledvičnega tubularnega izločanja kreatinina koncentracija kreatinina v plazmi poveča, vendar to ne pomeni nujno poslabšanja delovanja ledvic.
• That MULTAQ must not be used in patients with unstable haemodynamic conditions including patients with symptoms of heart failure at rest or with minimal exertion (corresponding to NYHA class IV and unstable class III patients). 
• Zdravila MULTAQ se ne sme uporabljati pri bolnikih z nestabilnimi hemodinamskimi stanji, vključno z bolniki, ki imajo simptome srčnega popuščanja v mirovanju ali med minimalnim naporom (to ustreza bolnikom v IV. razredu po NYHA in nestabilnim bolnikom v III. razredu po NYHA).
o Class I or Class III antiarrhythmics. 
o antiaritmiki iz I. in III. skupine.
• As the MULTAQ Information Card does not include all warnings or contraindications, the SPC should be referred to prior to prescribing MULTAQ and also prior to prescribing additional drugs to a patient already taking MULTAQ. 
• Informativna kartica o zdravilu MULTAQ ne vsebuje vseh opozoril ali kontraindikacij, zato je treba pred predpisovanjem zdravila MULTAQ prebrati njegov povzetek glavnih značilnosti; enako velja pred predpisovanjem dodatnih zdravil bolnikom, ki že jemljejo zdravilo MULTAQ.
The Marketing Authorisation Holder shall ensure that Health care professionals who intend to prescribe or dispense MULTAQ are provided with an SPCand the MULTAQ Information Card. 
Imetnik dovoljenja za promet bo poskrbel, da bodo vsi zdravstveni delavci, ki nameravajo predpisovati ali izdajati zdravilo MULTAQ dobili povzetek glavnih značilnosti zdravila (SmPC) in informativno kartico o zdravilu MULTAQ.
• Use with caution: in association with digoxin, beta blockers, calcium antagonists, statins and vitamin K antagonists. 
• Uporabljajte previdno: skupaj z digoksinom, zaviralci beta, kalcijevimi antagonisti, statini in antagonisti vitamina K.
o potential torsades de pointes inducers including phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides. 
o zdravila, ki lahko izzovejo torsade de pointes, vključno s fenotiazini, cisapridom, bepridilom, tricikličnimi antidepresivi, terfenadinom in nekaterimi peroralnimi makrolidi.
• Not recommended/to be avoided: o grapefruit juice, o potent CYP3A4 inducers including rifampicin, phenobarbital, carbamazepine, phenytoin, St John's Wort o dabigatran. 
• Nepriporočljiva/treba se jim je izogibati: o grenivkin sok, o močni induktorji CYP3A4, vključno z rifampicinom, fenobarbitalom, karbamazepinom, fenitoinom, šentjanževko, o dabigatran.
• That liver function tests should be performed prior and during treatment. 
• Pred zdravljenjem in med njim je potrebno opravljati teste jetrne funkcije.
• Contraindication: o CYP3A inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir. 
• Kontraindicirana: o zaviralci CYP3A vključno s ketokonazolom, itrakonazolom, vorikonazolom, pozakonazolom, telitromicinom, klaritromicinom, nefazodonom in ritonavirjem.
This summary was last updated in 08-2015. 
Povzetek je bil nazadnje posodobljen 08-2015.
Its use during the first three months of pregnancy is not recommended. 
Uporaba zdravila v prvem tromesečju nosečnosti ni priporočljiva.
The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998. 
Evropska komisija je dovoljenje za promet z zdravilom Kinzalmono, veljavno po vsej Evropski uniji, izdala 16. decembra 1998.
The full EPAR for Kinzalmono can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Kinzalmono je na voljo na spletni strani agencije: : ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Kinzalmono? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Kinzalmono?
This is a summary of the European public assessment report (EPAR) for Kinzalmono. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Kinzalmono.
Kinzalmono must not be used in women who are more than three months pregnant. 
Zdravila Kinzalmono ne smejo uporabljati ženske, ki so noseče več kot tri mesece.
A risk management plan has been developed to ensure that Kinzalmono is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Kinzalmono je bil pripravljen načrt obvladovanja tveganj.
The combination of the two medicines was no more effective than either medicine taken alone and was linked to an increased risk of side effects. 
Kombinacija obeh zdravil ni bila učinkovitejša od jemanja teh zdravil kot samostojnih zdravil in je bila povezana z večjim tveganjem za pojav neželenih učinkov.
If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide. 
Če želena vrednost krvnega tlaka ni dosežena, se lahko odmerek poveča na 80 mg ali pa doda drugo zdravilo za zdravljenje hipertenzije, kot je hidroklorotiazid.
Other information about Kinzalmono 
Druge informacije o zdravilu Kinzalmono
Kinzalmono is used to treat essential hypertension (high blood pressure) in adults. 
Zdravilo Kinzalmono se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Kinzalmono is a medicine that contains the active substance telmisartan. 
Kinzalmono je zdravilo, ki vsebuje zdravilno učinkovino telmisartan.
It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys). 
Uporablja se pri bolnikih, ki so imeli v preteklosti težave zaradi krvnih strdkov (kot so srčno obolenje, možganska kap ali bolezen arterij) ali pri katerih je sladkorna bolezen tipa 2 poškodovala enega od organov (kot so oči, srce ali ledvice).
What benefit has Kinzalmono shown during the studies? 
Kakšne koristi je zdravilo Kinzalmono izkazalo med študijami?
The CHMP decided that Kinzalmono's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Kinzalmono večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
For more information about treatment with Kinzalmono, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Kinzalmono preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Kinzalmono, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. 
Zdravilna učinkovina v zdravilu Kinzalmono, telmisartan, je „antagonist receptorjev angiotenzina II“, kar pomeni, da v telesu preprečuje delovanje hormona, imenovanega angiotenzin II.
This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke. 
To povzroči padec krvnega tlaka in zmanjšanje tveganja, ki je povezano z visokim krvnim tlakom, kot sta srčni infarkt ali možganska kap.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kinzalmono, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
For the prevention of cardiovascular problems, 80 mg Kinzalmono once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems. 
Za preprečevanje srčno-žilnih težav so zdravilo Kinzalmono v odmerku 80 mg enkrat dnevno proučevali v eni glavni študiji, v katero je bilo vključenih skoraj 26 000 bolnikov, starih 55 let ali več, ki so imeli srčno ali arterijsko bolezen, so doživeli možgansko kap ali imeli sladkorno bolezen in pri katerih je obstajalo veliko tveganje za srčno-žilne težave.
Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems. 
Hipotenzija je lahko pogostejša pri bolnikih, ki zdravilo Kinzalmono jemljejo za preprečevanje srčno-žilnih težav.
In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Kinzalmono must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension). 
Pri bolnikih s sladkorno boleznijo tipa 2 ali bolnikih z zmerno ali hudo okvaro ledvic se zdravilo Kinzalmono ne sme uporabljati v kombinaciji z zdravili, ki vsebujejo aliskiren (zdravilo za zdravljenje esencialne hipertenzije).